Meta-analysis of 249 RCTs (745,041 patients): in placebo-controlled trials, ACE inhibitors/ARBs (RR 0.69), MRAs and SGLT2 inhibitors (both RR 0.62) in HFrEF, SGLT2 inhibitors in CKD and GLP-1 RAs in obesity were linked to less incident AF; AF events were few.
Meta-analysisn = 745,041
Raveendra et al. Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis